Paysign (PAYS) Planet MicroCap Las Vegas 2026 summary
Event summary combining transcript, slides, and related documents.
Planet MicroCap Las Vegas 2026 summary
17 Jun, 2026Financial Performance and Growth
Achieved $82 million in FY2025 revenue, up 40.5% year-over-year, with adjusted EBITDA of $19.9 million, a 107% increase and gross margin at 59.4%.
Patient affordability business grew 116.9% to $40.9 million, now representing 41.3% of total revenue, up from 21.7% in 2024.
Plasma revenue was $45.6 million in FY2025, up 4.0% YoY, with mature recurring revenue.
Guidance for FY2026 projects $106.5–$110.5 million in revenue and $30–$33 million in adjusted EBITDA, with a roughly equal split between plasma and patient affordability.
Operating leverage is expanding, with SG&A as a percentage of revenue declining and EBITDA margin expected to reach ~29% in FY2026.
Business Model, Operations, and Technology
Operates a unified payments platform serving both plasma donor compensation and pharma patient affordability, leveraging a fixed infrastructure for scalable growth.
Holds approximately 45.5% share of the U.S. plasma payments market, serving 554 facilities and 8.4 million cardholders as of May 2026.
Proprietary Dynamic Business Rules technology delivers 97% first-fill detection accuracy, saving clients over $325 million in 2025 by preventing fraudulent copay claims.
Apherion platform offers modular, cloud-based solutions for donor engagement, CRM, compensation, and compliance, consolidating legacy point solutions.
Revenue models are variable and usage-based, including per-donation transactions, software subscriptions, and recurring management fees.
Market Opportunity and Outlook
Plasma payments market estimated at $110 million; patient affordability at $500–$750 million.
Plasma and blood center software market projected to grow from $3.5 billion to $7.5 billion in 10 years.
Both plasma and patient affordability markets are structurally growing, with significant runway for expansion in the U.S. and potential international opportunities.
Added 55 new programs in 2024 and expects to add 60 in 2025, with average revenue per program rising.
Investments in technology and operations are now yielding significant returns.
Latest events from Paysign
- FY2025 saw 40.5% revenue growth and a shift to balanced plasma and pharma revenue streams.PAYS
16th Annual East Coast IDEAS Conference11 Jun 2026 - FY2025 saw 40.5% revenue growth and expanding margins, with balanced plasma and pharma momentum.PAYS
Conference presentation18 May 2026 - Revenue up 50.8% and net income more than doubled, with strong margin expansion in Q1 2026.PAYS
Q1 202613 May 2026 - Annual meeting to elect seven directors and ratify auditor set for May 8, 2026.PAYS
Proxy filing26 Mar 2026 - Annual meeting to elect seven directors, ratify auditor, and highlight governance and compensation.PAYS
Proxy filing26 Mar 2026 - 2025 saw 40.5% revenue growth and margin expansion, with 2026 guidance projecting 30–35% growth.PAYS
Q4 202524 Mar 2026 - Rapid growth in patient affordability and tech-driven margin expansion offset plasma headwinds.PAYS
The MicroCap Rodeo Conference - NYC3 Feb 2026 - Strong revenue growth and market expansion in healthcare-focused prepaid payment solutions.PAYS
Small-Cap Growth Virtual Investor Conference3 Feb 2026 - Q2 revenue up 30% year-over-year, net income positive, and 2024 guidance raised.PAYS
Q2 20242 Feb 2026